Good evening :)
Place Order
Add to Watchlist

Alembic Ltd

ALEMBICLTD

Alembic Ltd

ALEMBICLTD
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,687 cr, stock is ranked 946
High RiskStock is 3.36x as volatile as Nifty
103.620.98% (-1.03)
103.620.98% (-1.03)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,687 cr, stock is ranked 946
High RiskStock is 3.36x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,687 cr, stock is ranked 946
High RiskStock is 3.36x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
8.461.222.32%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
48.676.190.55%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Alembic Limited is engaged in the business of pharmaceuticals, real estate and power assets. The Company's segments include API and Real Estate.

PE Ratio
43.75
1Y Return
13.24%
Buy Reco %
85.29
PE Ratio
28.85
1Y Return
0.99%
Buy Reco %
72.73
PE Ratio
62.82
1Y Return
17.26%
Buy Reco %
70.37
PE Ratio
53.95
1Y Return
14.92%
Buy Reco %
80.00
PE Ratio
18.28
1Y Return
3.43%
Buy Reco %
43.75
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 6.73%, vs industry avg of 9.04%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.07% to 0.06%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 4.74%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue162.76178.13162.32153.26167.3383.79167.40191.50212.26284.62
Raw Materialssubtract37.6450.9739.8645.2124.5911.778.536.928.62120.12
Power & Fuel Costsubtract13.265.461.112.340.910.420.152.021.18
Employee Costsubtract27.0128.6419.6420.5220.7922.6021.4724.0423.03
Selling & Administrative Expensessubtract7.627.387.137.269.177.569.8210.8114.04
Operating & Other expensessubtract45.6453.8046.4530.4115.1920.1024.3353.7353.76
Depreciation/Amortizationsubtract6.145.093.782.633.233.944.866.727.849.35
Interest & Other Itemssubtract0.120.160.170.220.290.360.390.471.112.33
Taxes & Other Itemssubtract-209.18-118.75-118.81-168.43-235.95-325.80-124.20-103.85-165.93-161.56
EPS7.154.434.976.6211.5013.358.657.4210.4612.24
DPS0.120.160.160.160.600.201.802.202.402.40
Payout ratio0.020.040.030.020.050.010.210.300.230.20

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Alembic Ltd9.911.222.32%
Sun Pharmaceutical Industries Ltd43.756.240.77%
Cipla Ltd28.854.440.88%
Torrent Pharmaceuticals Ltd62.8215.180.91%

Price Comparison

Compare ALEMBICLTD with any stock or ETF
Compare ALEMBICLTD with any stock or ETF
ALEMBICLTD
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding70.88%0.00%0.06%1.78%27.27%

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Shareholding History

SepDec '23MarJunSepDec '240.85%0.90%1.07%1.43%1.97%1.78%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 2.29%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹22.93 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 5, 2024

Final
Final | Div/Share: ₹2.40

Dividend/Share

2.40

Ex DateEx Date

Aug 5, 2024

Cash Dividend

Ex DateEx DateAug 3, 2023

Final
Final | Div/Share: ₹2.20

Dividend/Share

2.20

Ex DateEx Date

Aug 3, 2023

Cash Dividend

Ex DateEx DateSep 12, 2022

Final
Final | Div/Share: ₹1.80

Dividend/Share

1.80

Ex DateEx Date

Sep 12, 2022

Cash Dividend

Ex DateEx DateJul 29, 2021

Final
Final | Div/Share: ₹0.20

Dividend/Share

0.20

Ex DateEx Date

Jul 29, 2021

Cash Dividend

Ex DateEx DateJul 29, 2020

Final
Final | Div/Share: ₹0.60

Dividend/Share

0.60

Ex DateEx Date

Jul 29, 2020

News & Opinions
Spotlight
Alembic Q3 PAT soars to Rs 26 cr

Profit before tax (PBT) was at Rs 27.39 crore in Q3 FY25, up 151.75% as against Rs 10.88 crore reported in the same period a year ago. Total expense jumped 13.79% year on year to Rs 34.90 crore during the quarter. Employee benefit expense stood at Rs 6.56 crore (up 17.56% YoY), while cost of materials consumed was at Rs 1.81 crore (up 14.56% YoY) during the period under review. The company's revenue from the active pharmaceutical ingredients business was at Rs 6.25 crore (down 3.55% YoY), while the real estate business came in at Rs 51.67 crore (up 57.29% YoY) during the period under review. On a 9-month basis, the net profit surged 68.8% to Rs 120.83 crore on a 49.04% rise in revenue from operations to Rs 161.62 crore in 9M FY25 over 9M FY24. Alembic is dealing in the Active Pharmaceutical Ingredient (API) Business and Real Estate Business. Shares of Alembic fell 1.69% to Rs 110.85 on the BSE.Powered by Capital Market - Live

3 days agoCapital Market - Live
Earnings
Alembic consolidated net profit rises 6.50% in the December 2024 quarter

Net profit of Alembic rose 6.50% to Rs 65.39 crore in the quarter ended December 2024 as against Rs 61.40 crore during the previous quarter ended December 2023. Sales rose 47.30% to Rs 57.92 crore in the quarter ended December 2024 as against Rs 39.32 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales57.9239.32 47 OPM %45.5829.68 - PBDT30.0813.53 122 PBT27.3910.87 152 NP65.3961.40 6 Powered by Capital Market - Live

5 days agoCapital Market - Live
Corporate
Alembic to hold board meeting

Alembic will hold a meeting of the Board of Directors of the Company on 7 February 2025.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Earnings
Alembic consolidated net profit rises 33.46% in the September 2024 quarter

Net profit of Alembic rose 33.46% to Rs 121.02 crore in the quarter ended September 2024 as against Rs 90.68 crore during the previous quarter ended September 2023. Sales rose 63.91% to Rs 52.91 crore in the quarter ended September 2024 as against Rs 32.28 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales52.9132.28 64 OPM %37.0131.44 - PBDT84.5157.89 46 PBT81.8356.03 46 NP121.0290.68 33 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Alembic announces board meeting date

Alembic will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Alembic consolidated net profit rises 25.78% in the June 2024 quarter

Net profit of Alembic rose 25.78% to Rs 55.82 crore in the quarter ended June 2024 as against Rs 44.38 crore during the previous quarter ended June 2023. Sales rose 37.84% to Rs 50.78 crore in the quarter ended June 2024 as against Rs 36.84 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales50.7836.84 38 OPM %40.1729.53 - PBDT21.8713.38 63 PBT19.3711.55 68 NP55.8244.38 26 Powered by Capital Market - Live

6 months agoCapital Market - Live

Alembic’s shares dip amidst US market product recall

1 year agoThe Hindu Businessline

Housing & Urban Development Corporation Ltd leads gainers in ‘A’ group

2 years agoBusiness Standard

Alembic Ltd leads gainers in ‘A’ group

2 years agoBusiness Standard

This multibagger stock sets record date for 90% dividend

2 years agoLivemint